Bright Minds Biosciences Inc.

NASDAQ: DRUG · Healthcare · Biotechnology

Canadian filerHQ New York, NYCIK 0001827401Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 47

v0.1 · 5/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$2.1M

Employees

Market cap

$524.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$2.1M-2.8M CAD2024

Total assets$4.5M6.1M CAD2024

Liabilities$421.0k568.3k CAD2024

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Bright Minds Biosciences Inc. earned -$2.1M in FY2024 net income.

Peers · Healthcare

Pacific Biosciences of California, Inc.55C The Oncology Institute, Inc.52D Cabaletta Bio, Inc.——Nuvectis Pharma, Inc.——

Key facts

CEOIan McDonald

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York, NY

ExchangeNASDAQ: DRUG

Employees26

IPO date2021-03-22

Latest filings

6-K2026-06-03 6-K2026-06-02 6-K2026-05-28 6-K2026-05-20 6-K2026-02-13 6-K2026-01-09 6-K2026-01-09 6-K2026-01-08

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.